The blocking effect of PD-1/PD-L1 is generally expected to diminish with the interruption of ICIs because the binding of the anti-PD-1 antibody to PD-1-positive tumor-infiltrating CD8+ T cells is transient (20). Here, PDCD1 is linked to neoplasm.